Pomerantz said it is investigating potential securities fraud after DXC reported weaker fourth-quarter fiscal 2026 results, missed organic revenue guidance by about $75 million, and forecast another year of organic decline.
Pomerantz LLP said it is investigating claims on behalf of investors in DXC Technology Company over whether the company and certain of its officers and directors engaged in securities fraud or other unlawful business practices. The inquiry follows DXC’s May 7, 2026 release of fourth-quarter and full fiscal 2026 results, which showed revenue of about $3.13 billion, down 1.2% year over year and down 6.6% on an organic basis, and fourth-quarter bookings of about $3.3 billion, down 13.5% from a year earlier. During the earnings call, management said top-line performance missed expectations, that DXC fell short of its organic revenue guidance by about $75 million, or two percentage points, and that the shortfall reflected both pipeline and demand issues and execution problems. DXC also guided for fiscal 2027 organic revenue to decline about 3% to 5% year over year. The stock fell $2.58, or 21.48%, to close at $9.43 on May 8, 2026.